CNS drug development has had a significant revival. Anti-amyloid agents like Leqembi have shown meaningful slowing of Alzheimer’s progression, and Cobenfy’s 2024 approval marked the first non-dopaminergic schizophrenia treatment in...
Your Latest Best Estimate (LBE) forecast is the perfect partner to your Annual Operating Plan (AOP). Well, they are perfect partners when they work together effectively, which isn’t always –...
Evaluate is at Pharma CI 2026 in Newark, New Jersey, on 16 and 17 September, talking agentic AI, turning R&D benchmarks into competitor signals, and our new competitive intelligence agent,...
The Annual Operating Plan (AOP) and the Latest Best Estimate (LBE) are two of the most important forecasting processes a biotech or pharma commercial team runs. They are also among...
Oncology remains the largest segment in global pharma, accounting for around $241bn in 2025 prescription drug revenues. But portfolio momentum is fragmenting, and the next growth cycle looks materially different...
For many biotech businesses, value sits in the future potential of pipeline assets, clinical milestones, market opportunity, regulatory outcomes, competitive positioning and the probability of commercial success. For pre-revenue and...
